Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Molecular residual disease and adjuvant trials design in solid tumors.

Coakley M, Garcia-Murillas I, Turner NC.

Clin Cancer Res. 2019 May 14. pii: clincanres.0152.2019. doi: 10.1158/1078-0432.CCR-19-0152. [Epub ahead of print]

PMID:
31088829
2.

Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, McEwen R, Ratnayake J, Maudsley R, Carr TH, de Bruin EC, Schiavon G, Oliveira M, Turner NC.

Ann Oncol. 2019 Mar 12. pii: mdz085. doi: 10.1093/annonc/mdz085. [Epub ahead of print]

3.

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.

Lopez-Knowles E, Pearson A, Schuster G, Gellert P, Ribas R, Yeo B, Cutts R, Buus R, Garcia-Murillas I, Haynes B, Martin LA, Smith I, Turner N, Dowsett M.

Br J Cancer. 2019 Jan;120(2):247-255. doi: 10.1038/s41416-018-0345-x. Epub 2018 Dec 19.

PMID:
30563991
4.

Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.

Allin DM, Shaikh R, Carter P, Thway K, Sharabiani MTA, Gonzales-de-Castro D, O'Leary B, Garcia-Murillas I, Bhide S, Hubank M, Harrington K, Kim D, Newbold K.

Eur J Cancer. 2018 Nov;103:165-175. doi: 10.1016/j.ejca.2018.08.013. Epub 2018 Sep 22.

PMID:
30253333
5.

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC.

Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11.

6.

The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.

Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A.

Clin Cancer Res. 2018 Oct 1;24(19):4763-4770. doi: 10.1158/1078-0432.CCR-17-3374. Epub 2018 Jun 11.

7.

Assessing HER2 Amplification in Plasma cfDNA.

Garcia-Murillas I, Turner NC.

Methods Mol Biol. 2018;1768:161-172. doi: 10.1007/978-1-4939-7778-9_10.

PMID:
29717443
8.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC.

Nat Commun. 2018 Mar 1;9(1):896. doi: 10.1038/s41467-018-03215-x.

9.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M.

Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y.

10.

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.

Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner N.

Ann Oncol. 2018 Jan 1;29(1):145-153. doi: 10.1093/annonc/mdx483.

11.

Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.

Lee JY, Garcia-Murillas I, Cutts RJ, De Castro DG, Grove L, Hurley T, Wang F, Nutting C, Newbold K, Harrington K, Turner N, Bhide S.

Br J Cancer. 2017 Sep 5;117(6):876-883. doi: 10.1038/bjc.2017.258. Epub 2017 Aug 15.

12.

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC.

Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.

13.

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.

Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.

14.

Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.

Hrebien S, O'Leary B, Beaney M, Schiavon G, Fribbens C, Bhambra A, Johnson R, Garcia-Murillas I, Turner N.

PLoS One. 2016 Oct 19;11(10):e0165023. doi: 10.1371/journal.pone.0165023. eCollection 2016.

15.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC.

J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.

PMID:
27269946
16.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V.

Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Erratum in: Cancer Res. 2016 Oct 1;76(19):5907.

17.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

18.

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.

Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, Kozarewa I, Gonzalez de Castro D, Bhosle J, O'Brien M, Turner NC, Popat S, Downward J.

PLoS One. 2015 Sep 28;10(9):e0139074. doi: 10.1371/journal.pone.0139074. eCollection 2015.

19.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728
20.

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS.

Clin Cancer Res. 2015 Oct 15;21(20):4586-96. doi: 10.1158/1078-0432.CCR-15-0584. Epub 2015 Jun 17.

21.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

López-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I, Martin LA, Dowsett M.

Breast Cancer Res. 2014 Jun 30;16(3):R68. doi: 10.1186/bcr3683.

22.

Determination of HER2 amplification status on tumour DNA by digital PCR.

Garcia-Murillas I, Lambros M, Turner NC.

PLoS One. 2013 Dec 26;8(12):e83409. doi: 10.1371/journal.pone.0083409. eCollection 2013.

23.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
24.

An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer.

Garcia-Murillas I, Sharpe R, Pearson A, Campbell J, Natrajan R, Ashworth A, Turner NC.

Oncogene. 2014 May 8;33(19):2478-86. doi: 10.1038/onc.2013.202. Epub 2013 Jun 10.

25.

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC.

Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1.

26.

Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC.

Cancer Discov. 2012 Jun;2(6):524-39. doi: 10.1158/2159-8290.CD-11-0320. Epub 2012 Apr 23.

27.

Cellular apoptosis susceptibility (chromosome segregation 1-like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer.

Alnabulsi A, Agouni A, Mitra S, Garcia-Murillas I, Carpenter B, Bird S, Murray GI.

J Pathol. 2012 Dec;228(4):471-81. doi: 10.1002/path.4031. Epub 2012 Aug 20.

PMID:
22450763
28.

Rhabdomere biogenesis in Drosophila photoreceptors is acutely sensitive to phosphatidic acid levels.

Raghu P, Coessens E, Manifava M, Georgiev P, Pettitt T, Wood E, Garcia-Murillas I, Okkenhaug H, Trivedi D, Zhang Q, Razzaq A, Zaid O, Wakelam M, O'Kane CJ, Ktistakis N.

J Cell Biol. 2009 Apr 6;185(1):129-45. doi: 10.1083/jcb.200807027.

29.

lazaro encodes a lipid phosphate phosphohydrolase that regulates phosphatidylinositol turnover during Drosophila phototransduction.

Garcia-Murillas I, Pettitt T, Macdonald E, Okkenhaug H, Georgiev P, Trivedi D, Hassan B, Wakelam M, Raghu P.

Neuron. 2006 Feb 16;49(4):533-46.

30.

Functional INAD complexes are required to mediate degeneration in photoreceptors of the Drosophila rdgA mutant.

Georgiev P, Garcia-Murillas I, Ulahannan D, Hardie RC, Raghu P.

J Cell Sci. 2005 Apr 1;118(Pt 7):1373-84. Epub 2005 Mar 8.

Supplemental Content

Loading ...
Support Center